Dr. Reddy's Laboratories Ltd.
8-2-337, Road No. 3, Banjara Hills,
Hyderabad - 500 034, Telangana,
India.
CIN : L85195TG1984PLC004507

Tel :+91 40 4900 2900
Fax :+91 40 4900 2999
Email : mail@drreddys.com
www.drreddys.com

January 3, 2018

National Stock Exchange of India Ltd.
"Exchange Plaza"
Bandra-Kurla Complex, Bandra (East),
Mumbai – 400 051
Fax Nos.: 022-26598120/ 26598237/
26598238

Scrip Code: DRREDDY-EQ

Dear Sirs,

Ref.: Your email dated January 3, 2018

Sub: Clarification/confirmation on news item appearing in "Media/Publication".

This is with reference to your email dated January 3, 2018, seeking clarification about a news item which appeared in the www.moneycontrol.com dated January 3, 2018 captioned 'Dr. Reddy's cracks on buzz of issues raised in EIR for Duvvada plant.'

In this regard, we would like to state that the Company has already intimated the stock exchanges on November 21, 2017 regarding the updated status of USFDA audit of our Formulations Manufacturing Facility at Duvvada, Vishakhapatnam, Andhra Pradesh and has no further update.

Further, the movement in price of Company's scrip is completely market driven and hence the Company has no comments to offer on share price movement.

This is for your information and record.

With regards,

Sandeep Poddar
Company Secretary